The FDA assessed the protection and usefulness of atidarsagene autotemcel depending on information from 37 small children who gained atidarsagene autotemcel in two single-arm, open up-label medical trials As well as in an expanded accessibility program.[seven] Young children who received cure with atidarsagene autotemcel had been in comparison with